• Please click here to view the Final Program!!
Exhibition: Installation
April 26, 3:00 pm ~ April 27


Meeting Information
Faculty
• Course Directors
• Course Co-Directors
• Scientific Committee
• International Faculty
• Korean Faculty
• Associations and Affiliations
Scientific Program
• Meeting at a Glance
• Program Highlights
• Program
  - Main Arena
  - Coronary Arena
  - Endovascular Arena
  - Tutorial Arena
  - Breakfast Meetings
  - Satellite Symposia
  - Oral Abstract Presentation
  - Case Presentation
  - Live Case Operators
  - Conference for
    Cardiovascular Nurse
    & Technologist
  - Cardiopulmonary
    Rehabilitation Workshop
  - Clinical Exercise Specialist
    (CES) Workshop
Live Case Sites
Live Case Demonstration
TCTAP Live Interview
TCTAP Gallery
View E-poster Abstracts
Accepted Abstracts
Accepted Cases
Daily Newspaper
Advance Registration
Factoid
Syllabus
Visa Requirements
Housing
Exhibition
    & Promotion Activities
• General Information
• Exhibitor's List & Floor Plan
ACT Tour
Tour Information
• Korea, Sparkling
• About Seoul
  - Shopping in Korea
  - Food & Restaurant in Korea
• Tour Program
Contact Us
About CVRF
Floor Map Download
2010 Brochure Download

Thursday April 29, 2010
Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation: A Randomized, Multi-Center DES-LATE Trial
On Thursday morning, at 10:00 AM, the "Optimal Duration of Dual Antiplatelet therapy after Implantation of Drug-Eluting Stents" will be lectured at Main Arena by Seung-Jung Park, M.D., Ph.D., Professor of Medicine and Director of Interventional Cardiology, University of Ulsan College of Medicine at the ASAN Medical Center in Seoul, Republic of Korea.

Long-term safety of drug-eluting stents (DES) has been a serious concern due to an increased risk of late-occurring stent thrombosis, death, or myocardial infarction(MI). These serious outcomes can be reduced by administering dual antiplatelet therapy (DAPT); however, the optimal duration of DAPT administration following a DES implantation has not been validated.

Recently, the study of ˇ°Duration of Dual Antiplatelet Therapy after Implantation of Drug-eluting stentsˇ± was published on March 15, 2010, at NEJM.org. This study came out by merging data from two concurrent randomized controlled trials (REAL-LATE and ZEST-LATE) comparing clopidogrel continuation vs. discontinuation in patients who were event-free for......
Insight into LM PCI from MAIN-COMPARE
The five-year results of the MAIN-COMPARE registry study will be reported at Main Arena in Late Breaking Clinical Trials, April 29, at 9:40 am by Young-Hak Kim, M.D., Ph.D., Associate professor of Cardiology at University of Ulsan College of Medicine at the Asan Medical Center in Seoul, Republic of Korea.

Although coronary-artery bypass grafting (CABG) has been recommended as the standard care for patients with unprotected left main coronary artery (LMCA) disease, there are so many emerging data favorable for percutaneous coronary intervention (PCI) of those patients. On the basis of the evidence in......
Interactive Round Table Discussion featuring mini-lectures and case presentations
Breakfast Meeting, 7:00 AM - 8:10 AM

Transcatheter Aortic Valves: Complications during Percutaneous Aortic Valve Implantation
Eberhard Grube, MD

Many discussions were spotlighted today in morning roundtable forum at 7:00 am. There is a renewed enthusiasm in intervention at this TCTAP meeting in particular, "percutaneous aortic valve implantation". Eberhard Grube, MD., Chief of Cardiology/Angiology, Helios Heart Center Siegburg, Germany who was involved in this procedure since its real beginning, gave a lecture, "Complications during Percutaneous Aortic Valve Implantation". Obviously Percutaneous Aortic Valve Implantation started off with those patients who weren't candidates for surgery, and.....